Prohibits excessive increases in prices charged for essential off-patent and generic prescription drugs and biological products.

This bill prohibits manufacturers and distributors from excessively increasing prices for essential off-patent or generic prescription drugs and biological products without justification. It targets price hikes exceeding 50% within one year or exceeding $80 for a 30-day supply or full treatment, triggering an investigation by the Director of Consumer Affairs. Manufacturers must then justify the increase within 45 days by detailing production costs, cost changes, and public health efforts. Violations can result in court orders requiring price restoration, mandatory availability at prior prices, or civil penalties up to $10,000 per sale.